Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 64

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients

Darcy, David G., Chiaroni-Clarke, Rachel, Murphy, Jennifer M., Honeyman, Joshua N., Bhanot, Umesh, LaQuaglia, Michael P., Simon, Sanford M. · 2015 · Oncotarget

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2712

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 60

  1. Omata, 1980, Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features, Cancer, 46, 372, 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S · doi:10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s
  2. Meyers, 2007, Tumors of the liver in children, Surg Oncol, 16, 195, 10.1016/j.suronc.2007.07.002 · DOI · Paper page
  3. Sheahan, 1988, Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature, Hum Pathol, 19, 784, 10.1016/S0046-8177(88)80261-2 · doi:10.1016/s0046-8177(88)80261-2
  4. Williams, 2025, High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma, Br Med J (Clin Res Ed), 840
  5. Brock, 2013, Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma - Results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience, Eur J Cancer, 49, 2698, 10.1016/j.ejca.2013.04.012 · DOI
  6. Pawlik, 2014, Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective, Journal of the American College of Surgeons, 218, 196, 10.1016/j.jamcollsurg.2013.10.011 · DOI
  7. Ditah, 2014, Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis, Gastrointest Cancer Res, 7, 49
  8. Blumgart, 1984, Neurotensin secretion by fibrolamellar carcinoma of the liver, Lancet, 10, 538
  9. Evers, 1994, Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma, Ann Surg, 220
  10. Rossiter, 1986, Transcobalamin I as a “marker” for fibrolamellar hepatoma, Med Pediatr Oncol, 227
  11. Orsatti, Greenberg, Rolfes, Ishak, Paronetto. DNA ploidy of fibrolamellar hepatocellular carcinoma by image analysis. Hum Pathol. 1994/09/01; 936–9. · DOI
  12. Kreipe, 2000, Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization, Am J Clin Pathol [Internet], 114, 867, 10.1309/BMTT-JBPD-D13H-1UVD · doi:10.1309/bmtt-jbpd-d13h-1uvd
  13. Timmons, 1996, Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics, Cancer Genet Cytogenet, 170
  14. Habib, 1993, Infrequent chromosome allele loss in fibrolamellar carcinoma, Br J Cancer [Internet], 67, 244, 10.1038/bjc.1993.47 · doi:10.1038/bjc.1993.47
  15. Peters, 1986, Mitochondrial abnormalities in hepatocytes adjacent to fibrolamellar hepatocellular carcinoma, J Tongji Med Univ, 6, 26, 10.1007/BF02911614 · doi:10.1007/bf02911614
  16. Vivekanandan, Daniel, Yeh, Torbenson. Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol. 2010/03/17; 790–8. · DOI
  17. Belote, 2014, Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma, Science, 343, 1010, 10.1126/science.1249484 · DOI · Paper page
  18. Ding, 2012, MuSiC: identifying mutational significance in cancer genomes, Genome Res, 22, 1589, 10.1101/gr.134635.111 · DOI · Paper page
  19. Tanabe, 2014, Data, information, knowledge and principle: back to metabolism in KEGG, Nucleic Acids Res, 42, D199, 10.1093/nar/gkt1076 · DOI · Paper page
  20. McKenna, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature. Nature, 499, 214, 10.1038/nature12213 · DOI · Paper page
  21. Korbel, 2012, DELLY: structural variant discovery by integrated paired-end and split-read analysis, Bioinformatics, 28, i333, 10.1093/bioinformatics/bts378 · DOI · Paper page
  22. Edmondson, 1956, Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood, AMA J Dis Child, 91, 168
  23. Bowman, 2003, Fibrolamellar hepatocellular carcinoma in children and adolescents, Cancer, 2006
  24. Raymond, 2012, Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection, Cancer, 4981
  25. Hassan, 2013, Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma, Oncology, 85, 197, 10.1159/000354698 · doi:10.1159/000354698
  26. Klimstra, 2010, Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation, Mod Pathol [Internet], 23, 1180, 10.1038/modpathol.2010.105 · doi:10.1038/modpathol.2010.105
  27. Kiss, 2012, Molecular characteristics of fibrolamellar hepatocellular carcinoma, Pathol Oncol Res [Internet], 19, 63
  28. Buckley, Burgart, Kakar. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006/03/28; 410–4. · DOI
  29. Kinzler, 2013, Cancer genome landscapes, Science (New York, NY), 339, 1546, 10.1126/science.1235122 · DOI · Paper page
  30. Kufe, 2009, Mucins in cancer: function, prognosis and therapy, Nat Rev Cancer, 9, 874, 10.1038/nrc2761 · DOI · Paper page
  31. Carothers Carraway, 2009, Muc4/MUC4 functions and regulation in cancer, Future Oncol, 5, 1631, 10.2217/fon.09.125 · DOI
  32. Carraway, 2011, MUC1 and MUC4: switching the emphasis from large to small, Cancer Biother Radiopharm, 26, 261, 10.1089/cbr.2011.1017 · DOI
  33. Ranade, 2014, Genome Reference and Sequence Variation in the Large Repetitive Central Exon of Human MUC5AC, Am J Respir Cell Mol Biol, 50, 223, 10.1165/rcmb.2013-0235OC · DOI
  34. Stratton, 2008, The Catalogue of Somatic Mutations in Cancer (COSMIC), Curr Protoc Hum Genet
  35. Sunyaev, 2009, Human mutation rate associated with DNA replication timing, Nature Genetics, 41, 393, 10.1038/ng.363 · DOI · Paper page
  36. Hyrien, 2010, Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes, Genome Res, 20, 447, 10.1101/gr.098947.109 · DOI · Paper page
  37. Hashash, Thudi, Malik. An 18-year-old woman with a 15-cm liver mass and an ammonia level of 342. Gastroenterology. 2012/09/25; 1401; 1157–2. · doi:10.1053/j.gastro.2012.07.002
  38. Tejo, 2012, [Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma], Medicina (B Aires), 72, 425
  39. Revankar, 2009, Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma, Am J Med Sci, 338, 522, 10.1097/MAJ.0b013e3181bccfb4 · doi:10.1097/maj.0b013e3181bccfb4
  40. Liu, 2011, DNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular Carcinoma, Am J Pathol. Elsevier Inc, 178, 652, 10.1016/j.ajpath.2010.10.023 · DOI
  41. Fan, 2011, CREST maps somatic structural variation in cancer genomes with base-pair resolution, Nat Methods, 8, 652, 10.1038/nmeth.1628 · DOI · Paper page
  42. Runz, 2014, Sequencing of a patient with balanced chromosome abnormalities and neurodevelopmental disease identifies disruption of multiple high risk loci by structural variation, PLoS ONE, 9, e90894, 10.1371/journal.pone.0090894 · DOI
  43. Scherer, 2014, The Database of Genomic Variants: a curated collection of structural variation in the human genome, Nucleic Acids Res, 42, D986, 10.1093/nar/gkt958 · DOI · Paper page
  44. Waxman, 2011, Fibrolamellar Carcinoma: A Review with Focus on Genetics and Comparison to Other Malignant Primary Liver Tumors, Semin Liver Dis, 061
  45. Cleary, Jeck, Zhao, Selitsky. Identification of driver genes in hepatocellular carcinoma by exome sequencing - Cleary - Hepatology - Wiley Online Library. 2013. · DOI
  46. Chevet, 2012, Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nature Genetics, 44, 694, 10.1038/ng.2256 · DOI · Paper page
  47. Li, 2014, Long noncoding RNAs: Novel insights into hepatocelluar carcinoma, Cancer Lett, 344, 20, 10.1016/j.canlet.2013.10.021 · DOI · Paper page
  48. Shimotohno, 2006, Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues, Oncogene, 25, 2537, 10.1038/sj.onc.1209283 · DOI · Paper page
  49. Shibata, 2013, Comprehensive genome sequencing of the liver cancer genome, Cancer Lett, 340, 234, 10.1016/j.canlet.2012.10.035 · DOI
  50. Davidson, 2001, Genomic homogeneity in fibrolamellar carcinomas, Gut, 49, 82, 10.1136/gut.49.1.82 · doi:10.1136/gut.49.1.82
  51. Durbin, 2008, Mapping short DNA sequencing reads and calling variants using mapping quality scores, Genome Res, 18, 1851, 10.1101/gr.078212.108 · DOI · Paper page
  52. DePristo, 2010, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, 20, 1297, 10.1101/gr.107524.110 · DOI · Paper page
  53. Wilson, 2012, VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing, Genome Res, 22, 568, 10.1101/gr.129684.111 · DOI · Paper page
  54. Hall, 2010, BEDTools: a flexible suite of utilities for comparing genomic features, Bioinformatics, 26, 841, 10.1093/bioinformatics/btq033 · DOI · Paper page
  55. Ishii, 2011, High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child, J Pediatr Hematol Oncol. [Internet], e195
  56. Honda, Sbisa, Tullo, Papeo, Saccone, Poole, Pignatelli, Mitry, Ding, Isla, Davies, Habib. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer. 1998/03/26; 776–82. · DOI
  57. Schirmacher, 2005, Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis, Br J Cancer, 92, 935, 10.1038/sj.bjc.6602448 · DOI
  58. Kakar, Chen, Ho, Burgart, Sahai, Dachrut, Yabes, Jain, Ferrell. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol. Nature Publishing Group. Nov 7. 2008/11/11; 134–41. · doi:10.1038/modpathol.2008.178
  59. Marchio, Pineau, Meddeb, Terris, Tiollais, Bernheim, Dejean. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene. 3AD. Jul 30. 2000/08/19; 3733–8. · doi:10.1038/sj.onc.1203713
  60. Terracciano, Tornillo, Avoledo, Schweinitz Von, Kuhne, Bruder. Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14-year-old girl: a case report with comparative genomic hybridization analysis. Arch Pathol Lab Med. 2004/01/23; 222–6. · doi:10.5858/2004-128-222-fhcoya

Cited by

Metadata

Authors
Darcy, D. G., Chiaroni-Clarke, R., Murphy, J. M., Honeyman, J. N., Bhanot, U., LaQuaglia, M. P., & Simon, S. M.
Venue
Oncotarget
Published
2015-01-02
Volume
6
Issue
2
Pages
755-770
ISSN
1949-2553
Cited by
64
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.